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Streptococcus pneumoniae is a common cause of community-
acquired bacterial respiratory infections, including pneumonia, 
meningitis, bacteraemia, otitis media, and sinusitis, and is 
the pathogen least likely to resolve without treatment.1 The 
pneumococcus accounts for more than a third of acute bacterial 
sinusitis, over half of community-acquired bacterial pneumonia, 
and nearly a third of acute otitis media in children.  In adults it 
is responsible for 20 - 75% of community-acquired pneumonia, 
15 - 30% of acute exacerbations of chronic bronchitis, and 20 - 
40% of acute sinusitis.2 Of particular concern is the estimated 
annual incidence of 150 million cases of clinical pneumonia in 
children under 5 years of age in developing countries, with 11 - 
20 million severe enough to require hospitalisation, compared 
with an annual incidence of 2.1 million cases in developed 
countries.3  More than 4 800 deaths are estimated to have 
occurred from invasive pneumococcal disease in the USA in 
2005.4
The capsular polysaccharide is the major virulence factor for 
pneumococcal disease and also provides the antigenic target 
for production of protective antibodies either naturally or by 
vaccine. There are at least 90 immunologically distinct capsular 
serotypes in 21 numbered serogroups, each containing 2 - 5 
related serotypes, with a total of 65 such serotypes, and another 
25 individually numbered serotypes. Sequential serotypes of 
pneumococci colonise the nasopharynx, beginning within a 
few months of birth and continuing throughout adolescence 
and adulthood.5  Most serotypes colonise the nasopharynx 
for a month to a year, and are then replaced by another, with 
immunity developing to each colonising serotype sequentially, 
and duration and prevalence of colonisation decreasing with 
age. The prevalent serotypes carried differ between adults and 
children, with most of the serotypes carried by children under 
3 years of age belonging or related to those included in the 
recently licensed 7-valent protein-conjugated pneumococcal 
vaccine (4, 6B, 9V, 14, 18C, 19F, 23F), although serotypes 1, 
3, 5, and 7F are important in this age group in developing 
countries.6 Person-to-person transmission of S. pneumoniae is 
direct or through fomites, and is facilitated by crowding, such 
as in day-care centres. Pneumococcal disease occurs when an 
intercurrent event, such as an acute viral infection, damages the 
respiratory epithelium, resulting in infections of the middle ear 
space, mastoid air spaces, paranasal sinuses, bronchi and lung 
parenchyma, or in bacteraemia with haematogenous spread to 
other sites such as the meninges and joint spaces.
Work on pneumococcal vaccines began in 1911 in South 
Africa by Sir Almroth Wright and subsequently F Spencer Lister 
because of the extremely high incidence and mortality of lobar 
pneumonia in workers in gold and diamond mines.7 The annual 
incidence in one diamond mine between 1908 and 1911 was 
70 - 154 per 1 000 and mortality 14 - 29 per 1 000. The efficacy 
of these early, killed, whole-cell vaccines was striking, with the 
annual incidence of lobar pneumonia in this mine reduced to 
<5 per 1 000 and mortality <1 per 1 000 per year by 1916 - 1917. 
A similar result was reported by Cecil and Austin on a killed, 
whole-cell vaccine used in an American army camp in 1918. 
In 1977, the first modern pneumococcal vaccine, a 14-valent 
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Despite increasing resistance in the pneumococcus over 
the past 30 years, there are few cases of treatment failure 
of non-meningeal infections with high-dosage parenteral 
penicillin G, which still remains highly effective for 
many pneumococcal diseases. This is reflected by the 
new 2008 CLSI breakpoints for parenteral penicillin G of 
susceptible, ≤2 μg/ml, intermediate, 4 μg/ml, and resistant, 
≥8 µg ml, for non-meningeal infections.  For meningitis 
and oral penicillin V use, the old penicillin breakpoints of 
susceptible, ≤0.06 μg/ml, intermediate, 0.12 - 1 μg/ml, and 
resistant, ≥2 µg/ml, will remain in place.  Clinically relevant 
susceptibility breakpoints have also been developed for 
virtually all relevant antimicrobial agents used to treat 
pneumococcal diseases, based on clinical studies and 
pharmacokinetic and pharmacodynamic parameters. 
Although pneumococcal resistance to β-lactams, macrolides 
and co-trimoxazole is now common worldwide, we are still 
able to treat almost all pneumococcal infections adequately. 
An exception is the oral treatment of multidrug-resistant 
serotype 19A strains in children in the USA, as these are 
resistant to amoxicillin, oral cephalosporins, macrolides, 
clindamycin and co-trimoxazole. While there is a need to 
develop new agents, judicious use of antimicrobial agents is 
the best long-term approach. Empiric treatment guidelines 
should reflect the emerging threats from increased drug 
resistance and the possibility of increased virulence in 
replacement serotypes following vaccine use. Compliance 
with guidelines by physicians and patients is important to 
prevent further development of resistance.
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purified capsular polysaccharide vaccine targeted at elderly 
and high-risk populations, was approved.8,9 In 1983, it was 
replaced by a 23-valent polysaccharide vaccine (Pneumovax 23, 
Merck, Whitehouse Station, NJ) that included antigen from the 
23 serotypes that cause 88% of invasive diseases in adults and 
cross-reactivity for types that account for an additional 8% of 
invasive disease.10 The vaccine is estimated to be about 60 - 70% 
effective against invasive disease. As polysaccharide vaccines 
are ineffective in children under 2 years of age, various protein-
polysaccharide conjugated vaccines have been developed, and a 
7-valent vaccine (Prevnar, Wyeth-Lederle, Pearl River, NY) was 
introduced in the USA in 2000.11 The vaccine contains purified 
polysaccharides from the 7 serotypes commonly responsible for 
invasive disease in children in the USA, including the 5 most 
often found to be highly or multiply drug resistant. Recent 
studies have shown it to be efficacious in preventing invasive 
disease as well as carriage and associated respiratory infections 
caused by the vaccine serotypes.12 Less encouraging news is the 
emergence of replacement serotypes, particularly 19A, which 
are equally invasive and multiply drug resistant.13,14
Development of resistance
Pneumococcal disease was one of the first infectious 
diseases against which targeted therapy was aimed, with 
type-specific equine and rabbit antisera, optochin and early 
sulfonamides studied during the second and third decades 
of the 20th century.7,9 The introduction of penicillin G in the 
1940s replaced these earlier therapies, and the subsequent 
introduction of tetracyclines, chloramphenicol, macrolides, 
lincosamides, vancomycin, newer sulfonamides, trimethoprim, 
fluoroquinolones and linezolid provided additional therapeutic 
options.1,15,16 It is noteworthy that resistance to most of 
these antimicrobial agents was described soon after their 
introduction, although reports of resistance between 1950 and 
1975 were infrequent, and little penicillin resistance of clinical 
significance was reported. This situation changed drastically in 
1977 with the isolation of serotype 19A isolates from children 
with bacteraemia and meningitis in Durban and Johannesburg, 
South Africa, that were highly resistant to penicillin G and 
other β-lactams as well as chloramphenicol.17,18 These strains 
were resistant to ampicillin and chloramphenicol, the agents of 
choice for empiric treatment of meningitis at that time. Many 
of the Johannesburg isolates were also resistant to macrolides, 
lincosamides, tetracycline and trimethoprim-sulfamethoxazole.
Clinical significance of resistance
Since the largest number of prescriptions for antimicrobials is 
for respiratory infections in outpatients, there is considerable 
selective pressure on the pathogens causing these diseases. This 
generally occurs at the site of carriage of these bacteria (the 
nasopharynx) but can occasionally occur at the site of infection. 
In addition, the other colonising flora, such as viridans group 
streptococci, are exposed to these agents and often develop 
resistance which can in turn be transferred to S. pneumoniae. 
Resistance to antimicrobial agents in the major bacterial 
respiratory tract pathogens has increased alarmingly in recent 
years, leading to a need to re-evaluate empiric treatment 
choices. Drug resistance emerges more rapidly in the paediatric 
population than in adults, largely as a function of the 
higher frequency and density of bacterial colonisation of the 
nasopharynx in children.5 Antimicrobials should therefore be 
used judiciously as a large proportion of respiratory infections 
are viral in origin, where no antibiotic is indicated, and many 
bacterial infections resolve without antimicrobial treatment.19,20 
Our understanding of the relationships between in vitro 
and in vivo susceptibility of pneumococci has been limited by 
the lack of adequate clinical studies. These limitations have 
to a large extent been overcome recently with bacteriological 
outcome otitis media studies 21 and with the development 
of the field of pharmacokinetics and pharmacodynamics 
(PK/PD), which enables extrapolation of animal model 
data to humans.22 Pharmacokinetics describes the body’s 
absorption, distribution, metabolism, and elimination of drugs, 
while pharmacodynamics examines the in vivo relationship 
between the target pathogen and the antimicrobial agent 
over time, taking into account the effects of variations in drug 
concentrations on organism growth dynamics.  Antimicrobials 
can be divided into time- and concentration-dependent agents 
based on PK/PD relationships. For time-dependent agents such 
as β-lactams, the duration of the nonprotein-bound (free or 
active) drug concentration in plasma over time relative to the 
minimum inhibitory concentration (MIC) of the agent against 
a pathogen will determine in vivo bacterial killing. For S. 
pneumoniae the free (non-protein-bound) plasma concentration 
of a β-lactam should be above the MIC of the agent for at least 
30 - 35% of the dosing interval for penicillins, 40 - 50% for 
cephalosporins and 20 - 25% for carbapenems. Thus the free 
plasma concentrations of an agent, based on standard dosing 
regimens, achieved for the required proportion of the dosing 
interval can be determined and used as the susceptibility limit 
or pharmacodynamic breakpoint.22 Most agents other than 
β-lactams are concentration dependent, with the ratio of non-
protein-bound plasma area-under-the-curve (AUC) value over 
24 hours to MICs (AUC24:MIC ratio) correlated with in vivo 
efficacy.  Target AUC24:MIC ratios required for clinical success 
vary between drug classes, and are around 30 for macrolides, 
lincosamides and fluoroquinolones, and 80 for linezolid; 
susceptibility breakpoints for these agents can therefore 
be calculated by dividing AUC24 values by the applicable 
target. Susceptibility breakpoints for time- and concentration-
dependent agents based on plasma pharmacokinetics are 
generally applicable to extracellular infections at body sites 
where extracellular fluid levels are directly related to non-
protein-bound plasma levels, such as the respiratory tract and 
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dermis, but not to sites such as the central nervous system, 
where drug penetration may be limited. Application of PK/PD 
principles and appropriate clinical data has resulted in the 
development of clinically relevant breakpoints for S. pneumoniae 
infections for a variety of sites of infection and dosing regimens 
(Tables I and II).
Strains of S. pneumoniae were exquisitely susceptible to 
penicillin G, with MICs of ≤0.06 µg/ml when this agent was 
first introduced and used clinically in the 1940s and 1950s. In 
fact, the vast majority of strains at that time had penicillin G 
MICs ranging from 0.015 µg/ml to 0.03 µg/ml; this is therefore 
referred to as the baseline activity of penicillin G against ‘wild-
type’ S. pneumoniae.23 Decreased susceptibility to penicillin G 
among a few isolates of S. pneumoniae was noted in the 1960s in 
Australia and New Guinea, with MICs of 0.1 - 1 µg/ml; and in 
the 1970s in South Africa, isolates were noted to have penicillin 
G MICs as high as 2 - 4 µg/ml.17,18  Compared with fully 
susceptible isolates, the most resistant of these strains were 
only inhibited by a more than 200-fold greater concentration 
and other β-lactams. Penicillin G MICs at this time were 
arbitrarily classified by MIC range as susceptible (MICs ≤0.06 
µg/ml), intermediate (0.12 - 1 µg/ml) and resistant (≥2 µg/ml), 
as this had direct relevance to meningitis and to prediciting 
susceptibility of penicillin-susceptible isolates to other β-
lactams.18,22
However, this classification of penicillin MICs was confusing 
and led to inappropriate clinical applications; therefore, 
‘non-susceptible’ strains are best considered to be β-lactam 
challenged as this challenge can be overcome in many instances 
with appropriate dosing regimens. This situation has now 
largely been clarified by the Clinical and Laboratory Standards 
Institute (CLSI), with the development of clinically relevant 
susceptibility breakpoints for most β-lactams based on dosing 
regimen and site of infection, with breakpoints differing for 
meningeal and non-meningeal infections.24 The susceptible 
penicillin G breakpoint remains at ≤0.06 µg/ml for meningitis 
and for prediction of susceptibility to other β-lactams, while 
new susceptibility breakpoints for non-meningeal infections 
have been established at ≤2 μg/ml for parenteral penicillin G 
dosed at 12 million units/day and ≤4 μg/ml at 18 - 24 million 
units/day (≤2 μg/ml, susceptible; 4 μg/ml, intermediate;  
≥8 μg/ml, resistant).24 Recent international surveillance studies 
have demonstrated that about 50% of strains of S. pneumoniae 
still have penicillin G MICs in the ‘fully’ susceptible range of  
≤0.06 μg/ml, with 18 - 20% in the original intermediate range 
(0.12 - 1 μg/ml) and 12 - 33% in the original resistant range 
(≥2 μg/ml),25-27 and these interpretations are still valid for 
meningitis. Application of the new penicillin G breakpoints 
for non-meningeal infections to one dataset results in 92.6% 
of isolates being susceptible (≤2 μg/ml), 7.1% intermediate 
(4 μg ml) and 0.3% resistant (≥8 μg/ml) (Fig. 1).27 Although 
currently rare, highly penicillin G-resistant strains with MICs 
≥8 μg/ml are of concern should they proliferate.28
In general, the MIC distributions for all other β-lactams 
against S. pneumoniae also range over a greater than 200-fold 
concentration; however, there are significant differences among 
these agents with regard to the baseline activity,29 and each β-
lactam is best considered as an independent agent with its own 
breakpoints based on its pharmacokinetics and dosing regimen. 
Susceptibility breakpoints and susceptibility of relevant β-
lactams at these breakpoints for usual dosing regimens by site 
of infection are shown in Tables I and II. 
MIC distributions for other antimicrobial classes against 
which resistance has developed show distinct bimodal or 
trimodal patterns, with clear differentiation of ‘wild-type’ 
susceptible strains from resistant strains. Nonetheless, 
susceptibility breakpoints should be established based on PK/
PD parameters applicable to each agent and clinical studies to 
determine clinically relevant breakpoints. In most cases, the 
susceptible breakpoint falls between the susceptible ‘wild-type’ 
and resistant populations; susceptibilities of relevant agents at 
these breakpoints are shown in Tables I and II. 
Macrolides show a trimodal MIC distribution, representing 
‘wild-type’ strains with low MICs (<1 μg/ml), strains with 
efflux-mediated resistance with MICs usually 1 - 8 μg/ml 
for most macrolides, and strains with ribosomal methylase-
mediated resistance with MICs usually >64 μg/ml.23 Strains 
with efflux-mediated resistance are susceptible to lincosamides, 
while those with ribosomal methylase-mediated resistance are 
not. Considerable effort has been expended on determining 
where the clinically relevant macrolide breakpoints lie. Many 
studies have shown that the breakpoint is between the MICs 
of the ‘wild-type’ and efflux-resistant populations in all 
pneumococcal diseases, including pneumonia,15, 30-33  so this 
should no longer be a point of controversy, although some 
investigators still disagree.34 An agent related to macrolides, 
the ketolide telithromycin, is available in some countries, 
but its advantages, if any, over macrolides have not yet been 
adequately investigated.35 
Unimodal MIC distributions are found for vancomycin, 
linezolid, doxycycline and rifampicin, with susceptible 
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Fig. 1.  Histogram of penicillin G MICs of 8 882 isolates of  S. 
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Table II.  Adult and paediatric dosing regimens and susceptibility of antimicrobial agents used to treat pneumococcal 
infections.19,20,37,40,48,49 Dosing regimens are shown as total recommended daily dose and number of doses per day, and should be used 
in conjunction with local prescribing information. Susceptibility data reflect overall findings from international studies and local 
susceptibility data should be taken into consideration as susceptibility patterns vary considerably
 Antimicrobial agent
Total daily dose (number of doses per day)
Susceptible 
breakpoint (µg/
ml)*
Per cent 
susceptibility Data source Adults Infants and children
Parenteral agents – meningitis      
Penicillin G 24 million units (6) 300 000 - 400 000 U/kg  (4 - 6) ≤0.06 68.3 27
Ampicillin 12 g (6) 300 mg/kg  (4) Penicillin ≤0.06 68.3 27
Ceftriaxone 4 g (1 - 2) 100 mg/kg  (1 - 2) ≤0.5 82.2 - 86.2 27, 50 
Cefotaxime 8 - 12 g (4 - 6) 225 - 300 mg/kg  (4 - 6) ≤0.5 87.4 50
Cefepime 6 g (3) 150 mg/kg  (3) ≤0.5 85.3 50
Meropenem 6 g (3) 120 mg/kg  (3) ≤0.25 78.1 - 93.9 51
Vancomycin 30 - 60 mg/kg (3 - 4) 60 mg/kg  (4) ≤1 100 52
Rifampicin 600 mg (1) 20 mg  (1 - 2) ≤1 99.9 53
Chloramphenicol 4 - 6 g (4) 75 - 100 mg/kg  (4) ≤4 88.1 27
Parenteral agents – non-
meningeal infections
    
Penicillin G (regular dose) 12 million units (6) 250 000 - 400 000 U/kg  (4 - 6) ≤2† 92.6 27
Penicillin G (high dose) 18 - 24 million units (6) 400 000 U/kg  (4 - 6) ≤4 99.7§ 27
Ampicillin 4 - 8 g (4) 50 - 100 mg/kg (4) Penicillin ≤2 92.6 27
Ceftriaxone 1 - 2 g (1) 50 - 75 mg/kg  (1 - 2) ≤1 95.2 50
Cefotaxime 3 g (3) 75 - 100 mg/kg  (3 - 4) ≤1 95.1 - 96.5 27, 50 
Cefuroxime sodium 2.25 g (3) 50 - 100 mg/kg  (3 - 4) ≤0.5 75.3 50
Cefepime 2 g  (2) 100 mg/kg  (2) ≤1 96.5 50
Meropenem 1.5 - 3 g (3) 60 - 120 mg/kg  (3) ≤0.25 78.1 - 93.9 51
Imipenem 1 - 2 g (3 - 4) 60 mg/kg  (4) ≤0.12 92.4 - 96.3 51 
Ertapenem 1 g  (1) 30 mg/kg  (2) ≤1 93.2 - 93.3 26, 54
Vancomycin 2 g (2 - 4) 40 - 45 mg/kg  (3 - 4) ≤1 100 52
Oral agents     
Penicillin V 1 - 2 g (3 - 4) 25 - 50 mg/kg  (3 - 4) ≤0.06† 68.3 27
Amoxicillin (regular dose) 1.5 g (2 - 3) 45 mg/kg  (2 - 3) ≤2 95.1 27 
Amoxicillin/clavulanate 
(regular dose)
1.5 g/250 mg  (2 - 3) 45/6.4 mg/kg  (2 - 3) ≤2 95.5 27 
Amoxicillin (high dose) 6  (3) 90 mg/kg  (2 - 3) ≤4 97.9 27 
 Amoxicillin/clavulanate 
(high dose and extended 
release)
4 g/250 mg extended release  (2) 90/6.4 mg/kg  (2-3) ≤4 97.9 27 
Cefaclor 750 - 1 500 mg  (3) 20 - 40 mg/kg  (3) ≤0.5 60.2 27 
Cefuroxime axetil 500 - 1 000 mg  (2) 20 - 30 mg/kg  (2) ≤1 78.6 27 
Cefixime 400 mg  (1 - 2) 8 mg/kg  (1 - 2) ≤1 68.3 27 
Cefprozil 500 - 1 000 mg  (2) 15-30 mg/kg  (2) ≤1 79.7 27 
Cefdinir 600 mg  (1 - 2) 14 mg/kg  (1 - 2) ≤0.5 76.5 27 
Doxycycline 200 mg day 1, then 100 mg (1) NR‡ ≤0.25 71.3 27 
Co-trimoxazole 320/1 600 mg (2) 8/40 mg/kg  (2) ≤0.5/9.5 63.3 27 
Oral and parenteral agents     
Levofloxacin 500 - 750  (1) NR‡ ≤2 99.2 27 
Gemifloxacin 320  (1) NR‡ ≤0.25 99.9 27 
Moxifloxacin 400  (1) NR‡ ≤1 99.6 27 
Erythromycin 1 - 2 g  (4) 30 - 50 mg/kg  (4) ≤0.25 75.3 27 
Clarithromycin 500 - 750 mg  (1 - 2) 15 mg/kg  (2) ≤0.25 75.5 27 
Azithromycin 500 mg day 1, then 250 - 500 mg  (1) 10 mg/kg day 1, then 5 - 10 mg/kg  (1) ≤0.12 75.4 27 
Clindamycin 600 - 1 200 mg  (4) 8 - 16 mg/kg  (4) ≤0.25 86 27 
Linezolid 1 200 mg  (2) 30 mg/kg  (3) ≤2 100 50
*Susceptibility breakpoint for agent shown unless specified otherwise.
†Non-meningeal isolates susceptible to penicillin G at this breakpoint can be considered susceptible to parenteral ampicillin, cefepime, cefotaxime and ceftriaxone.  Non-meningeal isolates 
susceptible to ≤0.06 µg/ml of penicillin G can also be considered susceptible to these parenteral agents, as well as to parenteral ertapenem, imipenem and meropenem and to oral ampicillin, 
amoxicillin, amoxicillin/clavulanate, cefaclor, cefdinir, cefditoren, cefprozil, cefuroxime and cefpodoxime.
‡NR = not recommended for use in infants and children.
§Includes penicillin G susceptible (92.6%) and intermediate (7.1%) isolates based on new, non-meningeal, parenteral penicillin G susceptibility breakpoints.24
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breakpoints above the MIC distributions of these agents with 
the exception of doxycycline, where the breakpoint falls within 
the MIC distribution. Fluoroquinolones with antipneumococcal 
activity (e.g. levofloxacin, moxifloxacin and gemifloxacin) are 
highly active against the majority of strains of S. pneumoniae; 
however, resistance has been found in many areas and is 
clinically significant.36
Treatment of S. pneumoniae infections
Empiric treatment of diseases associated with S. pneumoniae 
infections should take into account the spectrum of common 
pathogens, the probability of pneumococcal involvement, and 
the degree of drug resistance commonly found in the patient’s 
geographical area.
Community-acquired pneumonia
The 2007 US treatment guidelines for empiric outpatient 
treatment of pneumonia in previously healthy adult patients 
without known risks for drug-resistant S. pneumoniae 
include a macrolide, such as azithromycin, clarithromycin, 
or erythromycin, or doxycycline.37 In outpatients with 
comorbidities or immunosuppressing conditions, or use of 
antimicrobials within the previous 3 months, or in regions 
with >25% macrolide resistance, and for non-ICU inpatients, 
the guidelines suggest using a macrolide in combination 
with a β-lactam, such as high-dose amoxicillin or amoxicillin 
clavulanate, preferentially, or cefpodoxime, cefuroxime or 
intramuscular (IM) ceftriaxone. Doxycycline may be used as 
an alternative to the macrolide. A respiratory fluoroquinolone, 
such as levofloxacin, moxifloxacin, or gemifloxacin, is also 
recommended as an alternative to a macrolide in combination 
with a β-lactam, particularly for β-lactam allergic patients. 
Guidelines in other regions generally recommend β-lactams 
such as amoxicillin rather than macrolides as first-line agents.38 
High-dose amoxicillin, either alone or with the addition of 
clavulanate, is recommended for first-line outpatient treatment 
of children with moderate disease severity.39 If oral antibiotics 
are not tolerated, daily IM ceftriaxone is recommended. 
Parenteral β-lactam agents, including penicillin G, cefotaxime 
and ceftriaxone, are recommended for hospitalised children, 
provided that appropriate doses of these agents are used.
Meningitis
Initial empiric treatment of meningitis for patients older than 
1 month is vancomycin plus a third-generation cephalosporin 
such as ceftriaxone or cefotaxime.40 In patients over 50 years of 
age, ampicillin should be added to cover Listeria monocytogenes. 
Treatment can be adjusted once culture and susceptibility 
results are obtained. For fully penicillin G-susceptible 
strains (penicillin G MICs ≤0.06 μg/ml), vancomycin can be 
discontinued, and treatment with cefotaxime or ceftriaxone 
continued, or high-dose penicillin G substituted. For strains 
with penicillin G MICs ≥0.1 μg/ml but susceptible to 
cefotaxime or ceftriaxone at their meningitis breakpoints (≤0.5 
μg/ml), vancomycin may also be discontinued. For isolates not 
susceptible to cefotaxime or ceftriaxone, one should continue 
treatment with the cephalosporin plus vancomycin, and 
monitor bacteriological outcome by repeat lumbar puncture; 
rifampicin may be added, and moxifloxacin can be considered 
as an alternative.40
Acute otitis media (AOM)
Practice guidelines published by the American Academy of 
Pediatrics and the American Academy of Family Physicians 
Subcommittee on Management of Acute Otitis Media 
recommend initial treatment with either amoxicillin   
80 - 90 mg/kg/day or, in the case of high temperature (>39°C) 
or severe otalgia, amoxicillin/clavulanate 90/6.4 mg/kg/day.19
Sinusitis
Fewer than 2% of cases of acute viral rhinitis are complicated 
by acute bacterial sinusitis.  Consequently, most cases 
of sinusitis can be treated conservatively with fluids 
and decongestants. Symptoms lasting more than a week 
or increasing in severity can be indicative of bacterial 
superinfection, with S. pneumoniae the most common bacterial 
pathogen. Treatment guidelines suggest treating paediatric 
patients with mild disease and no antibiotic exposure in the 
previous 4 - 6 weeks, with high-dose amoxicillin-clavulanate, 
high-dose amoxicillin, cefpodoxime proxetil, cefuroxime axetil, 
or cefdinir.20 Patients with β-lactam hypersensitivity can be 
treated with trimethoprim/sulfamethoxazole, azithromycin, 
clarithromycin, or erythromycin. Patients with more severe 
disease or recent antimicrobial use should be treated with 
high-dose amoxicillin-clavulanate, cefdinir, cefpodoxime or 
cefuroxime axetil. Beta-lactam-allergic patients should be 
treated as described above. Guidelines for adult patients are 
similar to those for paediatric patients, with the addition 
of respiratory fluoroquinolones such as levofloxacin or 
moxifloxacin, for treatment of more severe disease or treatment 
failure.20
Acute exacerbations of chronic bronchitis (AECB)
About 50% of acute episodes are estimated to be caused 
by bacteria, predominantly Haemophilus influenzae, with S. 
pneumoniae the next most frequent pathogen.41 More seriously 
ill patients, such as those with comorbidities or decreased 
respiratory function, or patients aged  >65, are best treated 
with either high-dose amoxicillin-clavulanate or a respiratory 
fluoroquinolone.42
Conclusions
Despite years of increasing in vitro penicillin G resistance in 
the pneumococcus, there are few cases of treatment failure of 
non-meningeal infections with high-dose parenteral penicillin 
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G.43-46 The new CLSI breakpoints for parenteral penicillin G of 
susceptible (≤2 μg/ml), intermediate (4 μg/ml), and resistant 
(≥8 µg/ml) reflected in the 2008 guidelines will greatly 
facilitate appropriate reporting and use of penicillin G. For 
meningitis and oral use, the old breakpoints of susceptible 
(≤0.06 μg/ml), intermediate (0.12 - 1 μg/ml), and resistant 
(≥2 µg/ml) remain in place for penicillin G and penicillin V. 
Susceptibility breakpoints have now been developed for 
virtually all relevant antimicrobial agents used to treat 
pneumococcal diseases, and application of PK/PD parameters 
has been of great assistance in the development of these 
breakpoints. Although pneumococcal resistance to β-lactams, 
macrolides and co-trimoxazole is now common worldwide, 
we are still able to treat almost all pneumococcal infections 
adequately. One exception is oral treatment of children with 
infections caused by resistant serotype 19A strains – the same 
resistant serotype found in South Africa in 1977, although 
of different clonal origin.47 Resistant serotype 19A strains 
are now common in the USA following introduction of a 
conjugate vaccine for use in children that contains serotype 
19F but not 19A polysaccharide; these strains are resistant to 
oral β-lactams including amoxicillin, as well as to macrolides, 
lincosamides and co-trimoxazole. While there is a need to 
develop new agents, judicious use of antimicrobial agents is 
the best long-term approach. Empiric treatment guidelines 
should continue to evolve to reflect the emerging threats from 
increased drug resistance and the possibility of increased 
virulence in replacement serotypes. It has been encouraging to 
note the increased use of watchful waiting in initial treatment 
guidelines. Compliance with guidelines by physicians and 
patients is important to prevent further development of 
resistance.
I am honoured to participate in this tribute to Hendrik Koornhof, 
my teacher, mentor, collaborator and colleague. This review is 
also dedicated to the memory of Robert Austrian, whose passion 
for the pneumococcus stimulated my interest in this organism, 
and whose recent passing marked the end of an era. I would also 
like to acknowledge the numerous individuals with whom I have 
collaborated on pneumococcal projects throughout the world; lack 
of space and memory lapses preclude me from naming you all. It 
is particularly gratifying for me that the initial investigation of the 
multiply resistant pneumococcal outbreak in which I participated 
in 1977 - 1978 has stood the test of time, and that the susceptibility 
methods and interpretations developed have been validated and 
have formed the basis of testing and interpretation currently in use 
worldwide.
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